molecules of the month


oral reversible BTK kinase inhibitor

Ph. I candidate for multiple sclerosis

from prior BTK inhibitor BIIB0685

Journal of Medicinal Chemistry


Chemical structure of molecule BIIB091 Biogen reversible BTK kinase inhibitor
1 min read

5.      The Biogen reversible BTK kinase inhibitor, BIIB091, is a highly selective, phase I clinical candidate for multiple sclerosis. Irreversible BTK inhibitors have been explored and developed extensively, primarily in cancer. Reversible molecules have been less common, with the most clinically advanced molecule being fenebrutinib (phase III). This molecule possesses an uncommon benzoazepine core and triazine amide, whose polarity contribute to favorable overall drug properties. The amine is rendered non-basic by the oxetane and other substitutions (pKa = 2.8), and the molecule is more polar than the typical active-site kinase inhibitor with corresponding properties (e.g. solubility >50 ug/mL, logD = 2.2, PPB fu = 18%) The Biogen team reported good safety in two preclinical species with a high NOAEL of 250 mg/kg in…

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: